Theranostics Products Revenues Increased 8% in the Three Months Ended March 31, 2024; Net Cash Provided By Operating Activities Was Approximately $400,000 in the Three Months Ended March 31, 2024; Gross Profit Increased 5% in the Three Months Ended March 31, 2024.  IDAHO FALLS, Idaho, May 16, 2024 /PRNewswire/ -- International Isotopes Inc. (OTCQB:INIS) (the "Company" or "INIS") announces its financial results for the three-month period ended March 31, 2024. Revenue for the three months ended March 31, 2024, was $2,904,458 compared to $3,089,535 for the same period in 2023.  This was an overall decrease of approximately 6%. The decrease in revenue for the three-month period was largely the result of continued global isotope shortages of Cobalt-57 isotopes impacting our Nuclear Medicine segment.  The Company reported a net loss for the three months ended March 31, 2024, of $154,051 compared to net loss of $148,054 for the same period in 2023. This is an increase in net loss of $5,997 that is largely the result of the decrease in revenue in our Nuclear Medicine Standards Products segment partially offset by increased revenue in our Theranostics Products and Cobalt Products segments and increased gross profit percentages for the three months ended March 31, 2024, as compared to the same period in 2023. As of March 31, 2024, cash and cash equivalents of $2,368,496 as compared to $2,688,141 at December 31, 2023. For the three months ended March 31, 2024, net cash provided by operating activities was $412,444 compared to $981,311 for the three months ended March 31, 2023. The following provides a summary of our current business segment performance for the three-month period ended March 31, 2024: Theranostics Products Revenue from the Theranostics Products segment increased approximately 8% for the three-month period ended March 31, 2024, compared to the same period in 2023. The increase was primarily the result of continued growth in demand for our radiopharmaceutical product (generic sodium iodide I-131).  This sodium iodide radiopharmaceutical drug is used to treat thyroid cancer and diseases, and we are currently the only domestic manufacturer of this important theranostic radiopharmaceutical drug product. We expect continued growth for our Theranostics Products segment for 2024 due to continued demand for generic sodium iodide I-131 products.  We also expect the addition of the EasyFill Automated Iodine Capsule System along with its consumables & accessories in our Medical Devices segment to support our sales in this segment. Nuclear Medicine Segment Revenue from nuclear medicine products for the three months ended March 31, 2024, was $765,408, compared to $1,168,831 for the same period in 2023. This represents a decrease in revenue of $403,423, or approximately 35%. The decrease is due to a global shortage of Cobalt-57 isotopes during the three months ended March 31, 2024. We continue to maintain a growing backlog of orders and we expect a revenue catch-up upon normalization of the global isotope supply chain, anticipated by the end of the third quarter of this year. Overall, we anticipate growth of the Nuclear Medicine Products segment upon normalization of the supply chain and as we continue to add new products, customers, and territories. Cobalt Products Revenue from the sale of Cobalt Products for the three months ended March 31, 2024, was $233,968, compared to $158,308 for the same period in 2023. This represents an increase of $75,660, or approximately 48%. Large value sales of high activity cobalt sources occur at various times throughout the year. Frequently the timing of these sales can have a significant impact on period comparisons. The Company remains the only domestic manufacturer and supplier of high activity cobalt-60 sealed-source products and we anticipate overall yearly growth in this segment in 2024 due to existing orders planned for manufacturing later this year. Medical Devices Medical Devices is a new reportable business segment starting in the first quarter of 2024. While we have not yet commercialized any medical devices, we have invested ...